Blog
Ipamorelin: the limits of an early selectivity study
The work explains research interest in ipamorelin. It supports a pharmacological distinction in the tested models, rather than broad human safety claims.
Evidence discussed: Laboratory and animal pharmacology.
What the researchers studied
An early development paper described ipamorelin as a growth-hormone secretagogue. Laboratory and animal experiments compared its hormone-release profile with other secretagogues. Its ACTH and cortisol responses differed from those of GHRP-2 and GHRP-6 under the tested conditions. [1]
How to interpret the result
Selectivity in an assay does not mean absence of every adverse effect. This was not a long-term human trial demonstrating muscle, sleep or anti-aging benefits. Species and experimental conditions affect interpretation.
What readers can take from it
The work explains research interest in ipamorelin. It supports a pharmacological distinction in the tested models, rather than broad human safety claims.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Raun et al., early ipamorelin pharmacology (1998). PMID: 9849822. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.